Astellas Pharma, Inc. v. Ranbaxy, Inc.

Federal Circuit

Astellas Pharma, Inc. v. Ranbaxy, Inc.

255 F. App'x 512

Court of Appeals for the Federal Circuit·Decided November 6, 2007·No. No. 2007-1199·Published

Opinion

ORDER

Defendants-Appellants Ranbaxy Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited and PlaintiffsAppellees Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc., having filed a consented Motion for an Order remanding the pending action to the District Court for further action by that court to effectuate a contingent settlement, and this Court having considered the consented Motion and for good cause shown, it is hereby,

ORDERED that the Motion is GRANTED. This case is remanded to the District Court.

Free access — add to your briefcase to read the full text and ask questions with AI

ORDER

Defendants-Appellants Ranbaxy Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited and PlaintiffsAppellees Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc., having filed a consented Motion for an Order remanding the pending action to the District Court for further action by that court to effectuate a contingent settlement, and this Court having considered the consented Motion and for good cause shown, it is hereby,

ORDERED that the Motion is GRANTED. This case is remanded to the District Court.

Astellas Pharma, Inc. v. Ranbaxy, Inc., 255 F. App'x 512 (Fed. Cir. 2007).

Pincite

255 F. App'x 512 (Astellas Pharma, Inc. v. Ranbaxy, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.